Melanoma vaccine may double stage IV survival. (Phase II Trial).: An article from: Skin & Allergy News

This digital document is an article from Skin & Allergy News, published by International Medical News Group on February 1, 2003. The length of the article is 504 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Melanoma vaccine may double stage IV survival. (Phase II Trial).
Author: Norra MacReady
Publication:Skin & Allergy News (Magazine/Journal)
Date: February 1, 2003
Publisher: International Medical News Group
Volume: 34 Issue: 2 Page: 31(1)

Distributed by Thomson Gale